Eun-Kee Song, Jun-Mo Yim, Joo-Yun Yim, Min-Young Song, Hye-Won Rho, Sung Kyun Yim, Yeon-Hee Han, So Yeon Jeon, Hee Sun Kim, Ho-Young Yhim, Na-Ri Lee, Jae-Yong Kwak, Myung-Hee Sohn, Ho Sung Park, Kyu Yun Jang, Chang-Yeol Yim
Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk 561-180, Republic of Korea.
Biochemical and biophysical research communications 2013 May 24Despite current immunosuppressive therapies, acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (HSCT). In the present study, therapeutic effects of intraperitoneal glutamine (Gln) administration (1g/kg/day) in a mouse aGVHD model were evaluated. Gln administration significantly inhibited the GVHD-induced inflammation and tissue injury in the intestine, liver, skin and spleen. Gln therapy improved the score of clinical evidence of aGVHD and prolonged the median survival of aGVHD mice. Gln administration in aGVHD mice increased the fraction of Foxp3+/CD4+/CD25+ cells in the blood measured on day 7, and decreased the serum levels of tumor necrosis factor-α measured on days 7, 14 and 21 after aGVHD induction. These results demonstrated that Gln administration may be useful in protecting the host from aGVHD. Copyright © 2013 Elsevier Inc. All rights reserved.
Eun-Kee Song, Jun-Mo Yim, Joo-Yun Yim, Min-Young Song, Hye-Won Rho, Sung Kyun Yim, Yeon-Hee Han, So Yeon Jeon, Hee Sun Kim, Ho-Young Yhim, Na-Ri Lee, Jae-Yong Kwak, Myung-Hee Sohn, Ho Sung Park, Kyu Yun Jang, Chang-Yeol Yim. Glutamine protects mice from acute graft-versus-host disease (aGVHD). Biochemical and biophysical research communications. 2013 May 24;435(1):94-9
PMID: 23624505
View Full Text